Clinical Trial Details


Research Study Summary

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment


To assess the efficacy and safety of SPN-810 in reducing the frequency of impulsive aggression (IA) behaviors in pediatric patients with ADHD when taken in conjunction with standard ADHD treatment.

To Learn more

CW ID: 213637
Date Last Changed: March 9, 2016

Clinical Trial Snapshot

Both Male and Female
6 to 12 Years
Overall Status
Lead Sponsor
Supernus Pharmaceuticals, Inc.
Facility Type


Inclusion Criteria:

  • Primary diagnosis of ADHD and currently receiving monotherapy treatment with an optimized FDA-approved ADHD medication
  • IA will be confirmed at screening using R-MOAS and Vitiello Aggression Scale

Exclusion Criteria:

  • Current or lifetime diagnosis of epilepsy, major depressive disorder, bipolar disorder, schizophrenia or related disorder, personality disorder, Tourette’s disorder, or psychosis not otherwise specified
  • Currently meeting DSM criteria for autism spectrum disorder, pervasive developmental disorder, obsessive compulsive disorder, post-traumatic stress disorder, or any other anxiety disorder as primary diagnosis


Colleen Figueroa
University of South Florida - USF Health Psychiatry Center
3515 E Fletcher Ave
Tampa, FL 33613
Phone: (813) 974-9104

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.